Our Pipeline> ANJ900 – Metformin DR

Type 2 Diabetes Therapy for Patients with Chronic Kidney Disease

ANJ900 offers improved glycemic control with reduced systemic exposure to metformin.

Bridging the Treatment Gap

ANJ900 controls blood sugar through a novel gut-targeted mechanism.

Gut-targeted Therapy Averts Serious Risks

ANJ900 leverages recent insight that the primary site-of-action of metformin, a mainstay of oral Type 2 diabetes therapy, is the region of cells lining the gut wall.

With this discovery, the dissolution of ANJ900 has been optimized to deliver metformin only where it’s needed. Gut-targeted therapy avoids unnecessary metformin absorption – a major safety risk for millions of Type 2 diabetes patients with chronic kidney disease.

ANJ900 Pivotal Trials

Two Phase 3 clinical trials are planned to support the New Drug Application (NDA) for ANJ900. The first trial (“DREAM-T2D”) is designed to show HbA1c lowering in T2D patients with moderate CKD (1-3B), and will utilize a 505(b)(2) pathway for FDA approval. The second trial (“DREAM-CKD”) will expand access of ANJ900 to patients with advanced CKD (3B and 4), getting this critical therapy to patients who need it most.

For partnerships, investment opportunities, or to learn more about our work, contact us.